A large consortium of European health-related stakeholders, including industry players, academia, healthcare professionals and patients, share their satisfaction on the draft adequacy decision on the UK data protection regime issued by the European Commission on 19th February 2021. Protecting the benefits of the free flow… read more
Following a successful launch event, the TRANSFORM MEP Interest Group, a multi-stakeholder alliance of Members of European Parliament, patient groups, academia and industry, published two important documents to lay the foundations of an open discussion on key priorities for gene and cell therapies, namely a… read more
On 8 December, the European Alliance for Transformative Therapies, a broad alliance of Members of European Parliament, patient groups, European Reference Networks, academia and industry, will be officially launched in a virtual meeting from 16.00 to 17.30. The Alliance, supported by MEPs Claudia Gamon (RE,… read more
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
Pharmaceutical small to mid-sized companies and start-ups constitute a laboratory of innovation and should be nurtured through a forward-looking European incentives ecosystem that encourages the development of cutting-edge technologies. The upcoming EU health policy initiatives, including the Pharmaceutical Strategy for Europe and the impact assessment… read more
EUCOPE, together with 33 other stakeholders active in health is delighted to invite you to the second EU Health Summit on 26 October. COVID-19 has exacerbated many of the existing, underlying problems of healthcare systems. The current crisis has clearly demonstrated how healthy populations and… read more
The EU and US Biotech Sector’s Response to COVID-19 On 24 September, EUCOPE, together with BIO, hosted a webinar focusing on the response of the global biotech sector to COVID-19 pandemic as well as measures taken by regulatory and policy institutions in the EU and… read more
Earlier this Summer the European Commission published its Roadmap for the Pharmaceutical Strategy for Europe which paved the way for a consultation process to which EUCOPE has contributed and will continue engage in the next months. Our position paper accompanying the general consultation is available… read more
EUCOPE, the European association for small to medium-sized companies in the field of pharmaceuticals, biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the study on the EU Regulation 141/2000 on Orphan Medicinal Products (OMPs) (here below)…. read more
EUCOPE examined with great interest the European Commission’s Pharmaceutical Strategy Roadmap. We welcome the European Commission’s acknowledgement of the crucial role played by the pharmaceutical sector in the economy of the EU, as well as the creation of a future-proof, knowledge-intensive European Union. We share… read more